Direct Answer
SEC EDGAR classifies Clorox under SIC major group 28. Among Swoopr's S&P 500 Equal Weight companies, 396 others share that classification; by latest reported revenue, Clorox ranks 27 of 397. A filing classification is a starting point: a company's real competitors depend on its segments, which its 10-K describes.
How Does Clorox Compare With Its Peers?
| Company | Revenue (latest FY) | Revenue growth | Operating margin | Net margin |
|---|---|---|---|---|
| Johnson & Johnson (JNJ) | $94.2 billion FY2025 | 6.0% | n/a | 28.5% |
| Procter & Gamble (PG) | $84.3 billion FY2025 | 0.3% | 24.3% | 19.0% |
| Eli Lilly (LLY) | $65.2 billion FY2025 | 44.7% | n/a | 31.7% |
| Pfizer (PFE) | $62.6 billion FY2025 | -1.6% | n/a | 12.4% |
| AbbVie (ABBV) | $61.2 billion FY2025 | 8.6% | 24.6% | 6.9% |
| Bristol Myers Squibb (BMY) | $48.2 billion FY2025 | -0.2% | n/a | 14.6% |
| Abbott Laboratories (ABT) | $44.3 billion FY2025 | 5.7% | 18.2% | 14.7% |
| Dow Inc. (DOW) | $40.0 billion FY2025 | -7.0% | n/a | -6.1% |
| Amgen (AMGN) | $36.8 billion FY2025 | 10.0% | 24.7% | 21.0% |
| Linde (LIN) | $34.0 billion FY2025 | 3.0% | 26.3% | 20.3% |
| LyondellBasell (LYB) | $30.2 billion FY2025 | -9.7% | -1.4% | -2.4% |
| Gilead Sciences (GILD) | $29.4 billion FY2025 | 2.4% | 34.0% | 28.9% |
| Colgate-Palmolive (CL) | $20.4 billion FY2025 | 1.4% | 16.2% | 10.5% |
| Ecolab (ECL) | $16.1 billion FY2025 | 2.2% | 17.0% | 12.9% |
| PPG Industries (PPG) | $15.9 billion FY2025 | 0.2% | n/a | 9.9% |
| Kenvue (KVUE) | $15.1 billion FY2025 | -2.1% | 16.0% | 9.7% |
| Estée Lauder Companies (EL) | $14.3 billion FY2025 | -8.2% | -5.5% | -7.9% |
| Viatris (VTRS) | $14.3 billion FY2025 | -3.0% | -18.6% | -24.6% |
| MOSAIC CO | $12.1 billion FY2025 | 8.4% | 6.8% | 4.5% |
| Air Products (APD) | $12.0 billion FY2025 | -0.5% | -7.3% | -3.3% |
| Vertex Pharmaceuticals (VRTX) | $12.0 billion FY2025 | 8.9% | 34.8% | 32.9% |
| Westlake Corporation (WLK) | $11.2 billion FY2025 | -8.0% | -14.1% | -13.5% |
| International Flavors & Fragrances (IFF) | $10.9 billion FY2025 | -5.2% | -3.5% | -3.3% |
| Biogen (BIIB) | $9.9 billion FY2025 | 2.2% | n/a | 13.1% |
| Zoetis (ZTS) | $9.5 billion FY2025 | 2.3% | n/a | 28.2% |
| RPM International Inc. (RPM) | $7.9 billion FY2026 | 6.7% | n/a | 8.4% |
| Clorox (CLX) | $7.1 billion FY2025 | 0.2% | n/a | 11.6% |
| CF Industries (CF) | $7.1 billion FY2025 | 19.3% | 32.5% | 25.4% |
| DuPont (DD) | $6.8 billion FY2025 | 1.9% | n/a | 1.3% |
| Olin Corporation (OLN) | $6.8 billion FY2025 | 3.7% | 0.1% | -1.5% |
| Organon & Co. (OGN) | $6.2 billion FY2025 | -2.9% | n/a | 3.0% |
| Church & Dwight (CHD) | $6.2 billion FY2025 | 1.6% | 17.4% | 11.9% |
| Huntsman Corporation (HUN) | $5.7 billion FY2025 | -5.8% | -2.3% | -5.0% |
| Albemarle Corporation (ALB) | $5.1 billion FY2025 | -4.4% | -7.1% | -9.9% |
| Axalta Coating Systems Ltd. (AXTA) | $5.1 billion FY2025 | -3.0% | 14.4% | 7.4% |
| Elanco Animal Health Incorporated (ELAN) | $4.7 billion FY2025 | 6.2% | n/a | -4.9% |
| Idexx Laboratories (IDXX) | $4.3 billion FY2025 | 10.4% | 31.6% | 24.6% |
| Solstice Advanced Materials Inc. (SOLS) | $3.9 billion FY2025 | 3.1% | n/a | 6.1% |
| Alnylam Pharmaceuticals (ALNY) | $3.7 billion FY2025 | 65.2% | 13.5% | 8.4% |
| Cabot Corporation (CBT) | $3.7 billion FY2025 | -7.0% | 16.7% | 8.9% |
| Scotts Miracle-Gro Company (The) (SMG) | $3.4 billion FY2025 | -3.9% | 10.5% | 4.3% |
| Avient Corporation (AVNT) | $3.3 billion FY2025 | 0.6% | 6.2% | 2.5% |
| BioMarin Pharmaceutical Inc. (BMRN) | $3.2 billion FY2025 | 12.9% | 12.7% | 10.8% |
| United Therapeutics Corporation (UTHR) | $3.2 billion FY2025 | 10.6% | 46.9% | 41.9% |
| Tronox Holdings plc (TROX) | $2.9 billion FY2025 | -5.7% | -8.7% | -16.2% |
| Neurocrine Biosciences Inc. (NBIX) | $2.9 billion FY2025 | 21.4% | 21.6% | 16.7% |
| NewMarket Corp (NEU) | $2.7 billion FY2025 | -2.2% | 20.0% | 15.4% |
| Royalty Pharma plc (RPRX) | $2.4 billion FY2025 | 5.1% | 65.6% | 32.4% |
| Exelixis Inc. (EXEL) | $2.3 billion FY2025 | 7.0% | 37.6% | 33.7% |
| Green Plains Inc. (GPRE) | $2.1 billion FY2025 | -14.9% | -3.2% | -5.8% |
| Valhi Inc. (VHI) | $2.1 billion FY2025 | -1.3% | 3.0% | -2.8% |
| Moderna (MRNA) | $1.9 billion FY2025 | -39.9% | -158.1% | -145.2% |
| Hexcel Corporation (HXL) | $1.9 billion FY2025 | -0.5% | 9.1% | 5.8% |
| Kronos Worldwide Inc (KRO) | $1.9 billion FY2025 | -1.5% | -2.0% | -6.0% |
| e.l.f. Beauty Inc. (ELF) | $1.6 billion FY2026 | 24.6% | 4.5% | 1.6% |
| Lantheus Holdings Inc. (LNTH) | $1.5 billion FY2025 | 0.5% | 20.2% | 15.2% |
| AdvanSix Inc. (ASIX) | $1.5 billion FY2025 | 0.3% | n/a | 3.2% |
| Halozyme Therapeutics Inc. (HALO) | $1.4 billion FY2025 | 37.6% | 33.6% | 22.7% |
| Bio-Techne (TECH) | $1.2 billion FY2025 | 5.2% | 8.4% | 6.0% |
| Novavax Inc. (NVAX) | $1.1 billion FY2025 | 64.7% | 40.3% | 39.2% |
| Madrigal Pharmaceuticals Inc. (MDGL) | $958 million FY2025 | 432.1% | -31.3% | -30.1% |
| Ionis Pharmaceuticals Inc. (IONS) | $944 million FY2025 | 33.8% | -40.4% | -40.4% |
| USANA Health Sciences Inc. (USNA) | $925 million FY2025 | 8.3% | 4.0% | 1.2% |
| Alto Ingredients Inc. (ALTO) | $918 million FY2025 | -4.9% | 0.8% | 0.0% |
| Tilray Brands Inc. (TLRY) | $915 million FY2026 | 11.5% | -6.9% | -13.3% |
| BioCryst Pharmaceuticals Inc. (BCRX) | $875 million FY2025 | 94.1% | 39.0% | 30.2% |
| Arrowhead Pharmaceuticals Inc. (ARWR) | $829 million FY2025 | 23258.2% | 11.9% | -0.2% |
| Myriad Genetics Inc. (MYGN) | $825 million FY2025 | -1.6% | -47.0% | -44.4% |
| Corcept Therapeutics Incorporated (CORT) | $761 million FY2025 | 12.8% | 5.9% | 13.1% |
| Emergent BioSolutions Inc. (EBS) | $743 million FY2025 | -28.8% | 13.5% | 7.1% |
| Repligen Corporation (RGEN) | $738 million FY2025 | 16.4% | 7.5% | 6.6% |
| Ecovyst Inc. (ECVT) | $724 million FY2025 | 20.9% | 9.0% | -9.8% |
| Kiniksa Pharmaceuticals International plc (KNSA) | $678 million FY2025 | 60.1% | 11.4% | 8.7% |
| Ultragenyx Pharmaceutical Inc. (RARE) | $673 million FY2025 | 20.2% | -79.5% | -85.4% |
| Axsome Therapeutics Inc. (AXSM) | $638 million FY2025 | 65.5% | -26.1% | -28.7% |
| LSB Industries Inc. (LXU) | $615 million FY2025 | 17.8% | 9.3% | 4.0% |
| OPKO Health Inc. (OPK) | $607 million FY2025 | -14.9% | -19.3% | -37187.0% |
| Insmed Incorporated (INSM) | $606 million FY2025 | 66.7% | -205.6% | -210.5% |
| Organogenesis Holdings Inc. (ORGO) | $564 million FY2025 | 17.0% | 7.9% | 6.6% |
| Mirum Pharmaceuticals Inc. (MIRM) | $521 million FY2025 | 54.7% | -4.2% | -4.5% |
| American Vanguard Corporation (AVD) | $515 million FY2025 | -5.9% | -5.5% | -9.7% |
| BridgeBio Pharma Inc. (BBIO) | $502 million FY2025 | 126.3% | -104.2% | -146.0% |
| Travere Therapeutics Inc. (TVTX) | $491 million FY2025 | 110.5% | -12.8% | -5.2% |
| Nature's Sunshine Products Inc. (NATR) | $480 million FY2025 | 5.7% | 5.2% | 4.1% |
| Tarsus Pharmaceuticals Inc. (TARS) | $451 million FY2025 | 146.7% | -15.7% | -14.6% |
| Ardelyx Inc. (ARDX) | $407 million FY2025 | 22.1% | -10.1% | -15.2% |
| Krystal Biotech Inc. (KRYS) | $389 million FY2025 | 33.9% | 41.5% | 52.6% |
| Twist Bioscience Corporation (TWST) | $377 million FY2025 | 20.3% | -36.2% | -20.6% |
| Arcutis Biotherapeutics Inc. (ARQT) | $376 million FY2025 | 91.3% | -3.3% | -4.3% |
| MannKind Corporation (MNKD) | $349 million FY2025 | 22.2% | 11.1% | 1.7% |
| CorMedix Inc. (CRMD) | $312 million FY2025 | 617.0% | 48.2% | 52.3% |
| Evolus Inc. (EOLS) | $297 million FY2025 | 11.6% | -11.0% | -17.4% |
| Ironwood Pharmaceuticals Inc. (IRWD) | $296 million FY2025 | -15.7% | 33.3% | 8.1% |
| Rigel Pharmaceuticals Inc. (RIGL) | $294 million FY2025 | 64.1% | 42.6% | 124.7% |
| Xeris Biopharma Holdings Inc. (XERS) | $292 million FY2025 | 43.7% | 8.5% | 0.2% |
| Adaptive Biotechnologies Corporation (ADPT) | $277 million FY2025 | 54.8% | -20.6% | -21.5% |
| Harrow Inc. (HROW) | $272 million FY2025 | 36.4% | 11.2% | -1.9% |
| Waldencast plc (WALD) | $272 million FY2025 | -0.7% | -80.0% | -84.4% |
| Iovance Biotherapeutics Inc. (IOVA) | $264 million FY2025 | 60.6% | -153.1% | -148.4% |
| Arvinas Inc. (ARVN) | $263 million FY2025 | -0.3% | -45.1% | -30.8% |
| Keros Therapeutics Inc. (KROS) | $244 million FY2025 | n/a | 27.7% | 35.7% |
| Flotek Industries Inc. (FTK) | $237 million FY2025 | 26.9% | 9.8% | 12.9% |
| Akebia Therapeutics Inc. (AKBA) | $236 million FY2025 | 47.5% | 9.9% | -2.2% |
| AnaptysBio Inc. (ANAB) | $235 million FY2025 | 157.0% | 96.7% | -5.6% |
| Lifevantage Corporation (LFVN) | $229 million FY2025 | 14.2% | 5.3% | 4.3% |
| Puma Biotechnology Inc (PBYI) | $228 million FY2025 | -0.9% | 16.3% | 13.6% |
| IDEAYA Biosciences Inc. (IDYA) | $219 million FY2025 | 3024.4% | -72.8% | -52.0% |
| Vanda Pharmaceuticals Inc. (VNDA) | $216 million FY2025 | 8.7% | -70.0% | -102.0% |
| Aemetis Inc. (AMTX) | $198 million FY2025 | -26.2% | -18.8% | -39.0% |
| Biote Corp. (BTMD) | $192 million FY2025 | -2.5% | 18.5% | 14.1% |
| Rhythm Pharmaceuticals Inc. (RYTM) | $190 million FY2025 | 45.8% | -101.2% | -0.1% |
| Maravai LifeSciences Holdings Inc. (MRVI) | $186 million FY2025 | -28.3% | -115.9% | -70.4% |
| Stoke Therapeutics Inc. (STOK) | $184 million FY2025 | 404.5% | -11.2% | -3.7% |
| CryoPort Inc. (CYRX) | $176 million FY2025 | 12.4% | -20.9% | 44.4% |
| Phathom Pharmaceuticals Inc. (PHAT) | $175 million FY2025 | 216.9% | -91.4% | -0.1% |
| Syndax Pharmaceuticals Inc. (SNDX) | $172 million FY2025 | 627.8% | -158.4% | -165.6% |
| REGENXBIO Inc. (RGNX) | $170 million FY2025 | 104.5% | -94.6% | -113.8% |
| Ginkgo Bioworks Holdings Inc. (DNA) | $170 million FY2025 | -25.1% | -185.3% | -0.2% |
| Maze Therapeutics Inc. (MAZE) | $168 million FY2024 | n/a | 34.4% | 31.2% |
| Gevo Inc. (GEVO) | $161 million FY2025 | 849.3% | -12.6% | -21.1% |
| NLI Holdings Inc. (NL) | $158 million FY2025 | 8.5% | 6.7% | -23.9% |
| Heron Therapeutics Inc. (HRTX) | $155 million FY2025 | 7.4% | -1.6% | -12.9% |
| MacroGenics Inc. (MGNX) | $150 million FY2025 | -0.3% | -48.7% | -0.0% |
| Karyopharm Therapeutics Inc. (KPTI) | $146 million FY2025 | 0.6% | -62.1% | -134.2% |
| Beam Therapeutics Inc. (BEAM) | $140 million FY2025 | 120.0% | -274.6% | -57.2% |
| Natural Alternatives International Inc. (NAII) | $130 million FY2025 | 14.1% | -6.7% | -10.5% |
| Niagen Bioscience Inc. (NAGE) | $129 million FY2025 | 29.9% | 12.6% | 13.4% |
| Lifecore Biomedical Inc. (LFCR) | $129 million FY2025 | 0.5% | -13.4% | -30.0% |
| Monte Rosa Therapeutics Inc. (GLUE) | $124 million FY2025 | 63.5% | -43.8% | -31.2% |
| Atara Biotherapeutics Inc. (ATRA) | $121 million FY2025 | -6.3% | 29.7% | 27.1% |
| Arq Inc. (ARQ) | $120 million FY2025 | 10.4% | -44.0% | -43.7% |
| Gyre Therapeutics Inc. (GYRE) | $117 million FY2025 | 10.2% | 9.9% | 8.5% |
| Agenus Inc. (AGEN) | $114 million FY2025 | 10.4% | -17.7% | -2.7% |
| ImmunityBio Inc. (IBRX) | $113 million FY2025 | 668.3% | -226.0% | -310.3% |
| Century Therapeutics Inc. (IPSC) | $109 million FY2025 | 1556.8% | -15.8% | -8.8% |
| Mannatech Incorporated (MTEX) | $108 million FY2025 | -8.3% | -0.4% | -14.1% |
| Zevra Therapeutics Inc. (ZVRA) | $106 million FY2025 | 350.9% | -59.1% | 78.2% |
| Zymeworks Inc. (ZYME) | $106 million FY2025 | 38.9% | -87.3% | -76.6% |
| Sutro Biopharma Inc. (STRO) | $102 million FY2025 | 65.2% | -154.5% | -186.4% |
| FutureFuel Corp. (FF) | $96 million FY2025 | -60.7% | -55.3% | -51.6% |
| SIGA Technologies Inc. (SIGA) | $95 million FY2025 | -31.8% | 25.1% | 24.6% |
| Cytokinetics Incorporated (CYTK) | $88 million FY2025 | 376.6% | -695.4% | -891.6% |
| Standard BioTools Inc. (LAB) | $85 million FY2025 | -6.2% | -129.2% | -87.8% |
| 4D Molecular Therapeutics Inc. (FDMT) | $85 million FY2025 | 230194.6% | -187.2% | -164.4% |
| ARS Pharmaceuticals Inc. (SPRY) | $84 million FY2025 | -5.5% | -212.9% | -203.3% |
| Nurix Therapeutics Inc. (NRIX) | $84 million FY2025 | 54.0% | -340.2% | -314.9% |
| MeiraGTx Holdings plc (MGTX) | $81 million FY2025 | 144.6% | -130.2% | -140.3% |
| Eton Pharmaceuticals Inc. (ETON) | $80 million FY2025 | 104.9% | -1.1% | -5.8% |
| CytomX Therapeutics Inc. (CTMX) | $76 million FY2025 | -44.8% | -29.3% | -22.8% |
| Ascent Industries Co. (ACNT) | $75 million FY2025 | -7.2% | -9.4% | 1.2% |
| Recursion Pharmaceuticals Inc. (RXRX) | $75 million FY2025 | 26.9% | -867.9% | -863.4% |
| Assembly Biosciences Inc. (ASMB) | $72 million FY2025 | 153.5% | -16.8% | -8.5% |
| Viridian Therapeutics Inc. (VRDN) | $71 million FY2025 | 23359.9% | -512.9% | -483.6% |
| Codexis Inc. (CDXS) | $70 million FY2025 | 18.6% | -59.3% | -62.5% |
| Black Diamond Therapeutics Inc. (BDTX) | $70 million FY2025 | n/a | 17.9% | 31952.9% |
| Rockwell Medical Inc. (RMTI) | $69 million FY2025 | -31.8% | -6.8% | -7.7% |
| Intellia Therapeutics Inc. (NTLA) | $68 million FY2025 | 16.9% | -651.7% | -609.9% |
| Kura Oncology Inc. (KURA) | $67 million FY2025 | 25.2% | -449.9% | -412.9% |
| Spero Therapeutics Inc. (SPRO) | $67 million FY2025 | 39.2% | 9.5% | 12.8% |
| Aytu BioPharma Inc. (AYTU) | $66 million FY2025 | 1.8% | -11.8% | -20.4% |
| Enanta Pharmaceuticals Inc. (ENTA) | $65 million FY2025 | -3.4% | -130.7% | -125.4% |
| Fortress Biotech Inc. (FBIO) | $63 million FY2025 | 9.7% | -111.0% | 58.5% |
| Nuvation Bio Inc. (NUVB) | $63 million FY2025 | 699.0% | -338.7% | -325.3% |
| Tango Therapeutics Inc. (TNGX) | $62 million FY2025 | 48.3% | -178.4% | -162.9% |
| Solesence Inc. (SLSN) | $62 million FY2025 | 18.6% | 2.5% | 2.9% |
| Journey Medical Corporation (DERM) | $62 million FY2025 | 10.2% | -13.2% | -18.5% |
| Champions Oncology Inc. (CSBR) | $59 million FY2026 | 4.4% | -1.9% | -0.0% |
| LanzaTech Global Inc. (LNZA) | $56 million FY2025 | 12.6% | -141.7% | -87.7% |
| Nektar Therapeutics (NKTR) | $55 million FY2025 | -43.9% | -253.7% | -296.9% |
| Agios Pharmaceuticals Inc. (AGIO) | $54 million FY2025 | 48.0% | -873.9% | -764.4% |
| Q32 Bio Inc. (QTTB) | $54 million FY2025 | n/a | 31.5% | 55.5% |
| Invivyd Inc. (IVVD) | $53 million FY2025 | 110.5% | -104.0% | -98.2% |
| Ocular Therapeutix Inc. (OCUL) | $52 million FY2025 | -18.5% | -519.8% | -511.9% |
| Lexicon Pharmaceuticals Inc. (LXRX) | $50 million FY2025 | 60.2% | -98.2% | -101.1% |
| Gossamer Bio Inc. (GOSS) | $48 million FY2025 | -57.7% | -352.2% | -351.5% |
| BioStem Technologies Inc. (BSEM) | $47 million FY2025 | -31.8% | -1.5% | -13.9% |
| Septerna Inc. (SEPN) | $46 million FY2025 | 4174.5% | -148.6% | -106.4% |
| Fennec Pharmaceuticals Inc. (FENC) | $45 million FY2025 | -6.1% | -14.1% | -21820.3% |
| Aquestive Therapeutics Inc. (AQST) | $45 million FY2025 | -22.6% | -159.5% | -188.1% |
| Cumberland Pharmaceuticals Inc. (CPIX) | $45 million FY2025 | 17.6% | -6.3% | -6.4% |
| Xilio Therapeutics Inc. (XLO) | $44 million FY2025 | 589.9% | -95.9% | -80.1% |
| Palvella Therapeutics Inc. (PVLA) | $43 million FY2023 | 65.3% | -27.7% | 43.7% |
| Coherus Oncology Inc. (CHRS) | $42 million FY2025 | 59.8% | -429.5% | 398.4% |
| Biofrontera Inc. (BFRI) | $42 million FY2025 | 11.7% | -27.2% | -25.3% |
| Equillium Inc. (EQ) | $41 million FY2024 | 13.9% | -20.1% | -19.6% |
| Alpha Teknova Inc. (TKNO) | $41 million FY2025 | 7.4% | -41.9% | -42.6% |
| Editas Medicine Inc. (EDIT) | $41 million FY2025 | 25.4% | -394.9% | -395.0% |
| Voyager Therapeutics Inc. (VYGR) | $40 million FY2025 | -49.5% | -326.6% | -296.5% |
| Kymera Therapeutics Inc. (KYMR) | $39 million FY2025 | -16.7% | -891.1% | 794.0% |
| C4 Therapeutics Inc. (CCCC) | $36 million FY2025 | 1.0% | -320.5% | -292.1% |
| Verrica Pharmaceuticals Inc. (VRCA) | $36 million FY2025 | 370.2% | -34.2% | -50.3% |
| Precision BioSciences Inc. (DTIL) | $34 million FY2025 | -50.1% | -152.2% | -133.4% |
| Verastem Inc. (VSTM) | $31 million FY2025 | 209.1% | -550.3% | -677.6% |
| Foghorn Therapeutics Inc. (FHTX) | $31 million FY2025 | 36.8% | -279.5% | -240.3% |
| Scilex Holding Company (SCLX) | $30 million FY2025 | -46.5% | -1143.7% | -1236.4% |
| ImmuCell Corporation (ICCC) | $28 million FY2025 | 4.3% | 6.0% | -3.8% |
| Cue Biopharma Inc. (CUE) | $27 million FY2025 | 195.7% | -96.7% | -96.9% |
| Celularity Inc. (CELU) | $27 million FY2025 | -51.0% | -230.9% | -345.4% |
| Entrada Therapeutics Inc. (TRDA) | $25 million FY2025 | -87.9% | -621.1% | -565.5% |
| Metagenomi Therapeutics Inc. (MGX) | $25 million FY2025 | -51.8% | -380.9% | -348.5% |
| Alumis Inc. (ALMS) | $24 million FY2025 | n/a | -1886.9% | -1011.7% |
| ASP Isotopes Inc. (ASPI) | $24 million FY2025 | 475.5% | -251.2% | -670.2% |
| Alector Inc. (ALEC) | $21 million FY2025 | -79.1% | -741.3% | -679.5% |
| SCYNEXIS Inc. (SCYX) | $21 million FY2025 | 449.9% | -78.0% | -41.8% |
| cbdMD Inc. (YCBD) | $19 million FY2025 | -1.5% | -11.3% | -10.6% |
| LENZ Therapeutics Inc. (LENZ) | $19 million FY2025 | n/a | -477.5% | -430.3% |
| Veru Inc. (VERU) | $17 million FY2024 | 3.6% | -214.2% | -223.9% |
| FitLife Brands Inc. (FTLF) | $16 million FY2025 | -75.3% | 18.6% | 39.7% |
| Neuphoria Therapeutics Inc. (NEUP) | $16 million FY2025 | n/a | -7.2% | -2.4% |
| Relay Therapeutics Inc. (RLAY) | $15 million FY2025 | 53.4% | -1971.6% | -1800.6% |
| Lineage Cell Therapeutics Inc. (LCTX) | $15 million FY2025 | 53.2% | -251.6% | -436.5% |
| Opus Genetics Inc. (IRD) | $14 million FY2025 | 29.1% | -271.9% | -349.3% |
| Pyxis Oncology Inc. (PYXS) | $14 million FY2025 | -14.2% | -609.2% | -574.5% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | $13 million FY2025 | 29.8% | -959.1% | -946.2% |
| Evommune Inc. (EVMN) | $13 million FY2025 | 85.7% | -623.6% | -529.8% |
| Elutia Inc. (ELUT) | $12 million FY2025 | -15.0% | -218.9% | 434.2% |
| Prelude Therapeutics Incorporated (PRLD) | $12 million FY2025 | 73.4% | -861.3% | -819.6% |
| Jaguar Health Inc. (JAGX) | $12 million FY2025 | -1.5% | -398.8% | -0.5% |
| Caribou Biosciences Inc. (CRBU) | $11 million FY2025 | 11.7% | -1329.4% | -1327.4% |
| Crescent Biopharma Inc. (CBIO) | $11 million FY2025 | n/a | -1407.5% | 1.4% |
| United-Guardian Inc. (UG) | $11 million FY2025 | -13.4% | 21.3% | 20.0% |
| TScan Therapeutics Inc. (TCRX) | $10 million FY2025 | 266.7% | -1315.4% | -1256.8% |
| Janux Therapeutics Inc. (JANX) | $10 million FY2025 | -5.6% | -1576.7% | -1136.3% |
| Zenas BioPharma Inc. (ZBIO) | $10 million FY2025 | 100.0% | -3830.6% | -3777.4% |
| Taysha Gene Therapies Inc. (TSHA) | $10 million FY2025 | 17.3% | -1130.6% | -1115.3% |
| Precigen Inc. (PGEN) | $10 million FY2025 | 146.7% | -1141.1% | -2587.8% |
| Prothena Corporation plc (PRTA) | $10 million FY2025 | -92.8% | -2216.4% | -2520.6% |
| Curis Inc. (CRIS) | $9 million FY2025 | -13.4% | -60.5% | -80.3% |
| BioAge Labs Inc. (BIOA) | $9 million FY2025 | n/a | -1031.5% | -896.1% |
| PureCycle Technologies Inc. (PCT) | $8 million FY2025 | n/a | -2171.6% | -2185.1% |
| Solid Biosciences Inc. (SLDB) | $8 million FY2022 | n/a | -1315.2% | -1062.3% |
| Coya Therapeutics Inc. (COYA) | $8 million FY2025 | 123.6% | -283.9% | -267.1% |
| Aclaris Therapeutics Inc. (ACRS) | $8 million FY2025 | -58.2% | -975.9% | -829.6% |
| Pulmatrix Inc. (PULM) | $8 million FY2024 | 7.0% | -125.1% | -122.5% |
| Bolt Biotherapeutics Inc. (BOLT) | $8 million FY2025 | 0.1% | -469.3% | -433.7% |
| Ovid Therapeutics Inc. (OVID) | $7 million FY2025 | 1181.3% | -585.2% | -239.9% |
| Whitehawk Therapeutics Inc. (WHWK) | $7 million FY2025 | -72.5% | -1601.1% | -288.3% |
| Tvardi Therapeutics Inc. (TVRD) | $7 million FY2024 | -66.0% | -393.8% | -411.9% |
| Immunome Inc. (IMNM) | $7 million FY2025 | -23.2% | -3228.8% | -3060.0% |
| Fate Therapeutics Inc. (FATE) | $7 million FY2025 | -51.2% | -2222.4% | -2051.1% |
| X4 Pharmaceuticals Inc. (XFOR) | $7 million FY2025 | 150.0% | -1336.7% | -1218.4% |
| Kyntra Bio Inc. (KYNB) | $6 million FY2025 | -78.3% | -712.7% | 2848.6% |
| Korro Bio Inc. (KRRO) | $6 million FY2025 | 181.5% | -1906.4% | -1834.5% |
| Abeona Therapeutics Inc. (ABEO) | $6 million FY2025 | n/a | -1536.9% | -1223.1% |
| TOMI Environmental Solutions Inc. (TOMZ) | $6 million FY2025 | -27.2% | -68.4% | -66.5% |
| Ensysce Biosciences Inc. (ENSC) | $5 million FY2025 | -2.8% | -202.1% | -200.8% |
| Prime Medicine Inc. (PRME) | $5 million FY2025 | 55.3% | -4498.1% | -4342.4% |
| Biomerica Inc. (BMRA) | $4 million FY2026 | -16.2% | -119.5% | -84.8% |
| Ocugen Inc. (OCGN) | $4 million FY2025 | 8.8% | -1425.7% | -1540.9% |
| Insight Molecular Diagnostics Inc. (IMDX) | $4 million FY2025 | 115.6% | -1260.8% | -1.2% |
| CG Oncology Inc. (CGON) | $4 million FY2025 | 254.7% | -4722.1% | -3985.1% |
| CervoMed Inc. (CRVO) | $4 million FY2025 | -58.9% | -706.2% | -673.2% |
| Cibus Inc. (CBUS) | $4 million FY2025 | -14.6% | -2680.1% | -3492.3% |
| Marker Therapeutics Inc. (MRKR) | $4 million FY2025 | -46.2% | -363.5% | -343.0% |
| CAMP4 Therapeutics Corporation (CAMP) | $3 million FY2025 | 436.5% | -1502.4% | -2298.5% |
| Surrozen Inc. (SRZN) | $3 million FY2025 | -67.4% | -1210.6% | -6960.8% |
| Aptevo Therapeutics Inc. (APVO) | $3 million FY2022 | n/a | -919.7% | 257.8% |
| Dyadic International Inc. (DYAI) | $3 million FY2025 | -11.6% | -232.8% | -238.3% |
| TherapeuticsMD Inc. (TXMD) | $3 million FY2025 | 71.6% | -145.3% | -18.8% |
| Xenetic Biosciences Inc. (XBIO) | $3 million FY2025 | 19.0% | -95.2% | -90.1% |
| Upstream Bio Inc. (UPB) | $3 million FY2025 | 20.4% | -5618.8% | -5026.0% |
| Cartesian Therapeutics Inc. (RNAC) | $3 million FY2025 | -92.8% | -5127.1% | -4658.6% |
| Traws Pharma Inc. (TRAW) | $3 million FY2025 | 1134.5% | -640.7% | 328.7% |
| GeoVax Labs Inc. (GOVX) | $2 million FY2025 | -37.1% | -869.3% | -862.3% |
| Elicio Therapeutics Inc. (ELTX) | $2 million FY2022 | n/a | -1031.4% | -1225.9% |
| SenesTech Inc. (SNES) | $2 million FY2025 | 19.6% | -292.9% | -287.4% |
| Aligos Therapeutics Inc. (ALGS) | $2 million FY2025 | -39.5% | -4024.9% | -1106.7% |
| Bonk Inc. (BNKK) | $2 million FY2025 | 201.6% | n/a | -3220.4% |
| Korsana Biosciences Inc. (KRSA) | $2 million FY2025 | 3.7% | -239.8% | -170.1% |
| Humacyte Inc. (HUMA) | $2 million FY2025 | n/a | -5306.0% | -2003.6% |
| Dianthus Therapeutics Inc. (DNTH) | $2 million FY2025 | -67.3% | -8739.3% | -7973.3% |
| Sagimet Biosciences Inc. (SGMT) | $2 million FY2023 | n/a | -1537.0% | -1393.8% |
| Lipocine Inc. (LPCN) | $2 million FY2025 | -82.3% | -524.7% | -487.2% |
| Rani Therapeutics Holdings Inc. (RANI) | $2 million FY2025 | 58.9% | -2346.0% | -1817.1% |
| Comstock Inc. (LODE) | $2 million FY2025 | -48.5% | -2455.2% | -2778.2% |
| Celldex Therapeutics Inc. (CLDX) | $2 million FY2025 | -78.0% | -18599.8% | -16748.0% |
| Perspective Therapeutics Inc. (CATX) | $1 million FY2023 | n/a | -2855.0% | -3243.2% |
| Outlook Therapeutics Inc. (OTLK) | $1 million FY2025 | n/a | -4744.3% | -4416.2% |
| Inhibrx Biosciences Inc. (INBX) | $1 million FY2025 | 550.0% | -10386.5% | -10773.5% |
| IGC Pharma Inc. (IGC) | $1 million FY2025 | -5.5% | -585.8% | -560.3% |
| Vistagen Therapeutics Inc. (VTGN) | $1 million FY2026 | 161.1% | -5683.7% | -5491.9% |
| NRX Pharmaceuticals Inc. (NRXP) | $1 million FY2025 | n/a | -1324.4% | -2336.5% |
| Longeveron Inc. (LGVN) | $1 million FY2025 | -49.9% | -1942.2% | -1893.6% |
| Matinas Biopharma Holdings Inc. (MTNB) | $1 million FY2023 | -65.6% | -2168.4% | -2093.2% |
| Dare Bioscience Inc. (DARE) | $1 million FY2025 | 10429.4% | -1315.5% | -1300.7% |
| 60 Degrees Pharmaceuticals Inc. (SXTP) | $1 million FY2025 | 65.5% | -771.6% | -732.5% |
| Shattuck Labs Inc. (STTK) | $1 million FY2025 | -82.5% | -5150.8% | -4880.9% |
| Rafael Holdings Inc. (RFL) | $917,000 FY2025 | 44.0% | -3179.8% | -3328.2% |
| ProKidney Corp. (PROK) | $893,000 FY2025 | 1075.0% | -18477.8% | -7725.2% |
| Rallybio Corporation (RLYB) | $858,000 FY2025 | 34.9% | -3853.6% | -1046.4% |
| Onconetix Inc. (ONCO) | $815,371 FY2025 | -67.7% | -2190.0% | -1721.0% |
| ImageneBio Inc. (IMA) | $800,000 FY2025 | -77.1% | -6056.4% | -5668.6% |
| Seres Therapeutics Inc. (MCRB) | $789,000 FY2025 | n/a | -11910.1% | 721.9% |
| Valion Bio Inc. (VBIO) | $780,000 FY2024 | -33.7% | -573.8% | -725.0% |
| Unicycive Therapeutics Inc. (UNCY) | $675,000 FY2023 | -29.0% | -3077.6% | -4525.0% |
| Lexeo Therapeutics Inc. (LXEO) | $654,000 FY2022 | n/a | -9252.1% | -9063.8% |
| Cardiff Oncology Inc. (CRDF) | $593,000 FY2025 | -13.2% | -8256.3% | -7.7% |
| PMGC Holdings Inc. (ELAB) | $590,084 FY2025 | n/a | n/a | -1313.0% |
| Ernexa Therapeutics Inc. (ERNA) | $582,000 FY2024 | 755.9% | -2693.1% | -7652.7% |
| Yarrow Bioscience Inc. (YARW) | $570,000 FY2025 | 13.8% | -5219.1% | -4646.1% |
| Imunon Inc. (IMNN) | $500,000 FY2022 | n/a | -4984.3% | -7179.6% |
| Pasithea Therapeutics Corp. (KTTA) | $486,559 FY2022 | n/a | -2587.3% | -2864.3% |
| Scienture Holdings Inc. (SCNX) | $431,609 FY2025 | 215.9% | -9867.9% | -9618.0% |
| Medicinova Inc (MNOV) | $409,657 FY2025 | n/a | -3242.5% | 2928.8% |
| iBio Inc. (IBIO) | $400,000 FY2025 | 77.8% | -4650.5% | -4595.0% |
| Allarity Therapeutics Inc. (ALLR) | $320,000 FY2025 | n/a | -3939.1% | -3509.7% |
| Vyome Holdings Inc. (HIND) | $319,714 FY2025 | 24.4% | -3269.4% | -3209.7% |
| ABVC BioPharma Inc. (ABVC) | $296,000 FY2025 | -41.9% | -2416.0% | -2671.8% |
| Geron Corporation (GERN) | $237,000 FY2023 | -60.2% | -81832.9% | -77690.7% |
| Anixa Biosciences Inc. (ANIX) | $210,000 FY2024 | 0.0% | -6586.2% | -5978.1% |
| Clene Inc. (CLNN) | $200,000 FY2025 | -41.5% | -11541.5% | -13086.5% |
| aTyr Pharma Inc. (ATYR) | $190,000 FY2025 | -19.1% | -40856.3% | -39009.5% |
| Lisata Therapeutics Inc. (LSTA) | $170,000 FY2025 | -83.0% | -10711.2% | -10000.0% |
| VivoSim Labs Inc. (VIVS) | $131,000 FY2026 | -9.0% | -8768.7% | -10567.2% |
| Serina Therapeutics Inc. (SER) | $130,000 FY2025 | 132.1% | -18478.5% | -14755.4% |
| Candel Therapeutics Inc. (CADL) | $125,000 FY2022 | n/a | -27777.6% | -15035.2% |
| Soligenix Inc. (SNGX) | $119,371 FY2024 | -85.8% | -7907.7% | -6953.1% |
| Bullfrog AI Holdings Inc. (BFRG) | $116,670 FY2025 | n/a | -5652.4% | -5569.6% |
| Actinium Pharmaceuticals Inc. (Delaware) (ATNM) | $90,000 FY2025 | n/a | -40274.4% | -37652.2% |
| Citius Pharmaceuticals Inc. (CTXR) | $90,000 FY2022 | n/a | -37017.8% | -37378.5% |
| Silo Pharma Inc. (SILO) | $72,102 FY2025 | 0.0% | -5937.0% | -5863.5% |
| eXoZymes Inc. (EXOZ) | $70,069 FY2023 | n/a | -2563.5% | -2909.1% |
| Inovio Pharmaceuticals Inc. (INO) | $65,343 FY2025 | -70.0% | -132871.3% | -130082.8% |
| Avalo Therapeutics Inc. (AVTX) | $59,000 FY2025 | -86.6% | -123601.7% | -132642.4% |
| Gain Therapeutics Inc. (GANX) | $55,180 FY2023 | -60.6% | -40328.3% | -40354.3% |
| HCW Biologics Inc. (HCWB) | $54,232 FY2025 | -97.9% | -24270.7% | -14677.1% |
| INmune Bio Inc. (INMB) | $50,000 FY2025 | 257.1% | -94766.0% | -92000.0% |
| Altimmune Inc. (ALT) | $41,000 FY2025 | 105.0% | -230461.0% | -214861.0% |
| NeOnc Technologies Holdings Inc. (NTHI) | $39,990 FY2025 | -51.8% | -145637.5% | -155404.4% |
| Oragenics Inc. (OGEN) | $37,653 FY2023 | -71.4% | -55519.9% | -54858.1% |
| Lyell Immunopharma Inc. (LYEL) | $36,000 FY2025 | -41.0% | -748344.4% | -762355.6% |
| Talphera Inc. (TLPH) | $28,000 FY2025 | n/a | -48157.1% | -51035.7% |
| Senti Biosciences Holdings Inc. (SNTI) | $22,000 FY2025 | n/a | -312631.8% | -279263.6% |
| Jupiter Neurosciences Inc. (JUNS) | $21,796 FY2025 | n/a | -40873.2% | -39662.8% |
| Cardio Diagnostics Holdings Inc. (CDIO) | $14,825 FY2025 | -57.5% | -43737.5% | -43832.5% |
| Genelux Corporation (GNLX) | $8,000 FY2025 | 0.0% | -415175.0% | -401812.5% |
| Aspire-Lakewood Holdings Inc. (ASBP) | $6,202 FY2025 | n/a | -312016.9% | -394725.1% |
| Creative Medical Technology Holdings Inc. (CELZ) | $6,000 FY2025 | -45.5% | -102380.2% | -99916.8% |
| Alaunos Therapeutics Inc. (TCRT) | $5,000 FY2025 | -50.0% | -84500.0% | -83520.0% |
| Caring Brands Inc. (CABR) | $4,215 FY2025 | n/a | -140807.2% | -148948.8% |
| Aardvark Therapeutics Inc. (AARD) | $0 FY2025 | n/a | n/a | n/a |
| Allogene Therapeutics Inc. (ALLO) | $0 FY2025 | -100.0% | n/a | n/a |
| ALX Oncology Holdings Inc. (ALXO) | $0 FY2022 | n/a | n/a | n/a |
| Amylyx Pharmaceuticals Inc. (AMLX) | $0 FY2025 | -100.0% | n/a | n/a |
| Annovis Bio Inc. (ANVS) | $0 FY2025 | n/a | n/a | n/a |
| Artiva Biotherapeutics Inc. (ARTV) | $0 FY2025 | -100.0% | n/a | n/a |
| Benitec Biopharma Inc. (BNTC) | $0 FY2024 | -100.0% | n/a | n/a |
| BeyondSpring Inc. (BYSI) | $0 FY2025 | n/a | n/a | n/a |
| BioCardia Inc. (BCDA) | $0 FY2025 | -100.0% | n/a | n/a |
| Capricor Therapeutics Inc. (CAPR) | $0 FY2025 | -100.0% | n/a | n/a |
| Compass Therapeutics Inc. (CMPX) | $0 FY2025 | -100.0% | n/a | n/a |
| Contineum Therapeutics Inc. (CTNM) | $0 FY2024 | -100.0% | n/a | n/a |
| Corbus Pharmaceuticals Holdings Inc. (CRBP) | $0 FY2022 | n/a | n/a | n/a |
| Cullinan Therapeutics Inc. (CGEM) | $0 FY2022 | n/a | n/a | n/a |
| Decoy Therapeutics Inc. (DCOY) | $0 FY2022 | n/a | n/a | n/a |
| Denali Therapeutics Inc. (DNLI) | $0 FY2025 | n/a | n/a | n/a |
| Design Therapeutics Inc. (DSGN) | $0 FY2025 | n/a | n/a | n/a |
| Eloxx Pharmaceuticals Inc. (ELOX) | $0 FY2025 | -100.0% | n/a | n/a |
| Exicure Inc. (XCUR) | $0 FY2025 | -100.0% | n/a | n/a |
| Fulcrum Therapeutics Inc. (FULC) | $0 FY2025 | -100.0% | n/a | n/a |
| Genprex Inc. (GNPX) | $0 FY2024 | n/a | n/a | n/a |
| Immuneering Corporation (IMRX) | $0 FY2023 | -100.0% | n/a | n/a |
| Inhibikase Therapeutics Inc. (IKT) | $0 FY2024 | -100.0% | n/a | n/a |
| KALA BIO Inc. (KALA) | $0 FY2025 | n/a | n/a | n/a |
| Kiora Pharmaceuticals Inc. (KPRX) | $0 FY2025 | -100.0% | n/a | n/a |
| Lightbridge Corporation (LTBR) | $0 FY2025 | n/a | n/a | n/a |
| Lite Strategy Inc. (LITS) | $0 FY2025 | -100.0% | n/a | n/a |
| Minerva Neurosciences Inc (NERV) | $0 FY2024 | n/a | n/a | n/a |
| Moleculin Biotech Inc. (MBRX) | $0 FY2025 | n/a | n/a | n/a |
| Monopar Therapeutics Inc. (MNPR) | $0 FY2025 | n/a | n/a | n/a |
| NanoViricides Inc. (NNVC) | $0 FY2025 | n/a | n/a | n/a |
| Nkarta Inc. (NKTX) | $0 FY2025 | n/a | n/a | n/a |
| Obsidian Therapeutics Inc. (OBX) | $0 FY2025 | n/a | n/a | n/a |
| OnKure Therapeutics Inc. (OKUR) | $0 FY2024 | n/a | n/a | n/a |
| Oruka Therapeutics Inc. (ORKA) | $0 FY2023 | n/a | n/a | n/a |
| Palatin Technologies Inc. (PTN) | $0 FY2025 | -100.0% | n/a | n/a |
| Palisade Bio Inc. (PALI) | $0 FY2025 | n/a | n/a | n/a |
| PharmaCyte Biotech Inc. (PMCB) | $0 FY2026 | n/a | n/a | n/a |
| Pliant Therapeutics Inc. (PLRX) | $0 FY2025 | n/a | n/a | n/a |
| Praxis Precision Medicines Inc. (PRAX) | $0 FY2025 | -100.0% | n/a | n/a |
| Processa Pharmaceuticals Inc. (PCSA) | $0 FY2022 | n/a | n/a | n/a |
| Rein Therapeutics Inc. (RNTX) | $0 FY2025 | n/a | n/a | n/a |
| Revolution Medicines Inc. (RVMD) | $0 FY2025 | n/a | n/a | n/a |
| Rocket Pharmaceuticals Inc. (RCKT) | $0 FY2025 | n/a | n/a | n/a |
| SAB Biotherapeutics Inc. (SABS) | $0 FY2025 | -100.0% | n/a | n/a |
| Scholar Rock Holding Corporation (SRRK) | $0 FY2025 | n/a | n/a | n/a |
| SELLAS Life Sciences Group Inc. (SLS) | $0 FY2023 | -100.0% | n/a | n/a |
| Spruce Biosciences Inc. (SPRB) | $0 FY2025 | -100.0% | n/a | n/a |
| Spyre Therapeutics Inc. (SYRE) | $0 FY2025 | n/a | n/a | n/a |
| Summit Therapeutics Inc. (SMMT) | $0 FY2024 | n/a | n/a | n/a |
| Tenax Therapeutics Inc. (TENX) | $0 FY2025 | n/a | n/a | n/a |
| TuHURA Biosciences Inc. (HURA) | $0 FY2025 | n/a | n/a | n/a |
| Viking Therapeutics Inc. (VKTX) | $0 FY2025 | n/a | n/a | n/a |
| vTv Therapeutics Inc. (VTVT) | $0 FY2025 | -100.0% | n/a | n/a |
| XBiotech Inc. (XBIT) | $0 FY2023 | -100.0% | n/a | n/a |
| XCF Global Inc. (SAFX) | $0 FY2025 | n/a | n/a | n/a |
| Zentalis Pharmaceuticals Inc. (ZNTL) | $0 FY2025 | -100.0% | n/a | n/a |
Revenue growth compares each company's latest fiscal year with the one before. Fiscal years do not always end on the same date, so treat close comparisons with care.
Where These Numbers Come From
Every figure on this page is a value Clorox reported in its own SEC filings, read from the SEC's XBRL data (accession 0000021076-25-000039 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 12, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary.
Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation.
Frequently Asked Questions
Who are Clorox's competitors?
Companies sharing Clorox's SEC classification (SIC major group 28) include Johnson & Johnson (JNJ), Procter & Gamble (PG), Eli Lilly (LLY), Pfizer (PFE), AbbVie (ABBV). Its 10-K names the competitors it considers most relevant.
How does Clorox compare with its peers on margins?
A margin comparison needs reported operating income for Clorox and its peers; where either is missing, Swoopr leaves the comparison out.
How are these peers chosen?
By the SEC Standard Industrial Classification code each company files under, within Swoopr's S&P 500 Equal Weight company set, falling back to the two-digit major group when fewer than two companies share the exact code. Classification codes are broad, so read the peer list as a screen, not a verdict.